Press Releases for YMI

Press Releases
YM BIOSCIENCES USA RECEIVES CLEARANCE FROM US TREASURY DEPARTMENT TO EXTEND CLINICAL PROGRAM FOR NIMOTUZUMAB
YM BIOSCIENCES USA RECEIVES CLEARANCE FROM US TREASURY DEPARTMENT TO EXTEND CLINICAL PROGRAM FOR NIMOTUZUMAB
YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG
YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG
YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
YM BIOSCIENCES ANNOUNCES FIRST PATIENT ENROLLED IN MULTI-NATIONAL, RANDOMIZED, DOUBLE-BLIND TRIAL OF NIMOTUZUMAB IN NON-SMALL-CELL LUNG CANCER
YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
YM BIOSCIENCES REPORTS SECOND QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS - PR Newswire
YM BIOSCIENCES REPORTS SECOND QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS - CNW
YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
YM BIOSCIENCES' NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
YM BIOSCIENCES' NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
YM BIOSCIENCES PROVIDES EU REGULATORY UPDATE
YM BIOSCIENCES PROVIDES EU REGULATORY UPDATE
Notice of YM Biosciences Annual and Special Meeting of Shareholders
YM BIOSCIENCES SUBSIDIARY CIMYM NOTIFIES ONCOSCIENCE AG OF INTENTION TO SUBMIT ISSUES FOR ARBITRATION
YM BIOSCIENCES SUBSIDIARY CIMYM NOTIFIES ONCOSCIENCE AG OF INTENTION TO SUBMIT ISSUES FOR ARBITRATION
YM BIOSCIENCES RESPONDS TO BBM ANNOUNCEMENT
BBM Announces Offer to Acquire YM BioSciences Inc.
YM BIOSCIENCES REPORTS FIRST QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
YM BIOSCIENCES REPORTS DATA FROM EXPLORATORY CLINICAL TRIALS OF NIMOTUZUMAB IN BRAIN METASTASES AND HIGH-GRADE GLIOMA PRESENTED AT 2008 EORTC-NCI-AACR ANNUAL MEETING
YM BIOSCIENCES REPORTS DAIICHI AND KUHNIL ENROL FIRST PATIENTS IN RANDOMIZED PHASE II GASTRIC TRIAL
YM BIOSCIENCES REPORTS FISCAL YEAR END 2008 OPERATIONAL AND FINANCIAL RESULTS
YM BIOSCIENCES ANNOUNCES STAFFING CHANGES
NOTICE OF YM BIOSCIENCES CONFERENCE CALL TO DISCUSS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER
NOTICE OF YM BIOSCIENCES CONFERENCE CALL TO DISCUSS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER
YM BIOSCIENCES REPORTS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER
YM BIOSCIENCES REPORTS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER
YM BIOSCIENCES PRESENTS DATA COMPARING MECHANISM OF ACTION FOR EGFR ANTIBODY, NIMOTUZUMAB TO CETUXIMAB AND PANITUMUMAB, AT THE AACR CENTENNIAL CONFERENCE ON TRANSLATIONAL CANCER MEDICINE 2008
Revised Analyst Reports for Rubicon Minerals Corporation, YM BioSciences Inc., Ableauctions.Com Inc., And FieldPoint Petroleum Corporation
Wall Street Media Presents Exclusive Videos from the Collins Stewart Fourth Annual Growth Conference
YM BIOSCIENCES ANNOUNCES FDA LIFTS CLINICAL HOLD ON AEROLEF(R) AND CLEARANCE OF A PHASE II CLINICAL TRIAL
YM BIOSCIENCES ANNOUNCES FDA LIFTS CLINICAL HOLD ON AEROLEF(R) AND CLEARANCE OF A PHASE II CLINICAL TRIAL
NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING
NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING
YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
YM BIOSCIENCES REPORTS FISCAL THIRD QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
YM BIOSCIENCES ANNOUNCES SCHEDULE OF NIMOTUZUMAB PRESENTATIONS AT ASCO 2008 ANNUAL MEETING
YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR AEROLEF(TM) AT AMERICAN PAIN SOCIETY ANNUAL MEETING - Jun 2 2008 3:01AM
YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR TWO OF ITS ANTI-CANCER DRUGS AT AACR ANNUAL MEETING